Floatz logo

KETOROLAC

Migraine Without Aura

University of AlbertaSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Migraine Without Aura cohort.

Asset / SponsorPhaseRating
Topiramate
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 4BBB
DHE
Satsuma Pharmaceuticals, Inc.
Phase 3BBB
Apsolol
Norwegian University of Science and Technology
Phase 3BB
METOCLOPRAMIDE
Assistance Publique - Hôpitaux de Paris
Phase 4BB
Rimegepant
University of South Florida
Phase 4BB

View all 50 →

Same molecule, other indications

KETOROLAC is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
72 / 100
View asset →
substance-related disorderActive
BB
Indicative · Phase 3
65 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →